Johns Hopkins Receives $72 Million To Help Translate Scientific Discoveries To Improved Health
The Johns Hopkins University will receive $72 million over the next four years to bolster its clinical research program at its Institute for Clinical and Translational Research, or ICTR. With this funding, Johns Hopkins aims to increase the number and improve the efficiency and value of clinical trials conducted at Johns Hopkins over the next few years.
“We have a very strong clinical research program and a solid infrastructure to support translational research, and this funding allows our younger researchers to bring new ideas, new treatments and new devices into the testing phase,” says Daniel Ford, M.D., vice dean for clinical investigation at the Johns Hopkins University School of Medicine.
To help speed translational research, the Johns Hopkins ICTR provides funding for pilot studies, clinical space and staffing, biostatistics expertise and ethics and regulatory support. With this new grant, the ICTR will create three new translational research “communities.” These communities will provide researchers with the partnerships, science methodology and technical support to help faculty bring their most promising ideas related to development of drugs, biologics, diagnostic tests and behavioral interventions more quickly to market and the broader community. The grant is supported by the Clinical and Translational Science Awards (CTSA), a program led by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, which supports a consortium of more than 60 research institutions across the country, all focused on strengthening translational research.
“Science and technology are progressing at an unprecedented pace, and the CTSA program — which represents NIH’s largest single investment in clinical research — is helping researchers harness these innovations and deliver improved diagnostics, treatments and cures for disease,” said NIH Director Francis S. Collins, M.D., Ph.D.
About - Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading academic health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's vision, “Together, we will deliver the promise of medicine,” is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and 31 primary health care outpatient sites. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years in a row by U.S. News & World Report.
The National Center for Advancing Translational Sciences (NCATS) is a distinctly different entity in the research ecosystem. Rather than targeting a particular disease or fundamental science, NCATS focuses on what is common across diseases and the translational process. The center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate improvements in translational science that bring about tangible improvements in human health. For more information, visit www.ncats.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 institutes and centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical and translational medical research, and is investigating the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. View descriptions of these awardees and other CTSA institutions at www.ncats.nih.gov/ctsa-funded.html.
To learn more about how CTSA-supported investigators are translating basic discoveries into improved health, visit www.ncats.nih.gov/ctsa.html.
To learn more about the Johns Hopkins Institute for Clinical and Translational Research, visit http://ictr.johnshopkins.edu/.